{"protocolSection":{"identificationModule":{"nctId":"NCT05355831","orgStudyIdInfo":{"id":"H-20036199"},"organization":{"fullName":"Herlev Hospital","class":"OTHER"},"briefTitle":"Patient-tailored Transcranial Direct Current Stimulation to Improve Stroke Rehabilitation","officialTitle":"Patient-tailored Transcranial Direct Current Stimulation to Improve Stroke Rehabilitation","acronym":"PRACTISE"},"statusModule":{"statusVerifiedDate":"2022-12","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-08-28","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-08","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-04-26","studyFirstSubmitQcDate":"2022-04-26","studyFirstPostDateStruct":{"date":"2022-05-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-12-13","lastUpdatePostDateStruct":{"date":"2022-12-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Christina Kruuse","investigatorTitle":"Study Principal Investigator, Consultant Neurologist, Dept. Neurology, Herlev Hospital","investigatorAffiliation":"Herlev Hospital"},"leadSponsor":{"name":"Christina Kruuse","class":"OTHER"},"collaborators":[{"name":"Danish Research Centre for Magnetic Resonance","class":"OTHER"},{"name":"The Novo Nordic Foundation","class":"OTHER"},{"name":"University of Copenhagen","class":"OTHER"},{"name":"Lundbeck Foundation","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"In a double-blinded sham-controlled study the effect of patient-tailored transcranial direct current stimulation during rehabilitation training will be examined.","detailedDescription":"Approximately two thirds of stroke patients have reduced motor function which have a large impact on both activities of daily living and quality of life. Only 12-34% achieve full motor recovery.\n\nThere is a growing interest in using non-invasive brain stimulation (NIBS) techniques to supplement neurorehabilitation. NIBS can modulate cortical excitability and is a powerful tool for motor rehabilitation post-stroke. Application Transcranial Direct Current Stimulation (TDCS) is currently emerging as a tool used in neurorehabilitaiton. Prior studies have shown that TDCS-stimulation prior to physical training may significantly improve of motor function post-stroke. However, up to 50% of the participants recieving active TDCS show no response to stimulation.\n\nA one-size-fits-all approach to TDCS in stroke rehabilitation may not be optimal and a more precise and individualized targeting is warranted to stimulate functionally relevant areas.\n\nIn this study TDCS will be personalized for stroke patients with upper-extremity paresis using individual functional and structural Magnetic Resonance Imaging (MRI) and an electric field modelling pipeline developed at Danish Research Centre for Magnetic Resonance (DRMCR). Based on these measures the electric current induced by TDCS will individually target the area with residual neural activity during movement. The effect of personalized TDCS will be assessed by clinical measures of motor improvement. Sub-studies furthermore assess if the functional reorganization of motor networks is affected by personalized TDCS by application of functional magnetic resonance (fMRI) and.\n\nThe study will have 3 phases:\n\n1. Personalization: The stimulation profile of each patient will be individualized using structural MRI a pipeline for simulation based on MRI (SimNIBS) to make individual anatomical head models in order to estimate the best montage and current dosage. Further, task-based fMRI will be used to estimate residual motor activity location. The target current is set in the area displaying the highest residual motor activity in sensorimotor areas.\n2. Intervention: Four weeks upper extremity training program of specialized supervised physiotherapeutic training 3 times per week. Each training session consists of 2x 20 minutes of training with concurrent personalized TDCS stimulation or montage of equipment but no stimulation (sham). Each bloc of 20 minutes training is separated by a small break of 5-10 minutes. Both patient, therapist and investigator will be blinded to the stimulation mode (activ TDCS or sham)\n3. Follow-up: Immediately after the 4 weeks of intervention and 12 weeks after intervention has ended, follow-up with clinical examination and brain MRI will be done.\n\nAd baseline Transcranial Magnetic Stimulation (TMS) will be done as well to assess corticospinal integrity as well as estimation of intracortical inhibition.\n\nHypothesis:\n\nThe main hypothesis is that personalized ipsi-lesional anodal TDCS during specialized individualized arm-training will lead to significantly greater improvements in upper-extremity motor function compared to sham.\n\nSubstudy with healthy controls:\n\nA cohort of 20 healthy age- and sex matched controls will be recruited for one session of MRI and TMS identical to the procedure of the patients at baseline as well as the same questionnaires (Protocol amendment approved by the local Ethics Committee the 10th October 2022).\n\nThese data will be analyzed in a substudy for normative comparison between the stroke patients and healthy age- and sex-matched controls.\n\nHypothesis - Healthy Controls:\n\nStroke patients will exhibit a higher laterality index measured by fMRI and a stronger degree of interhemispheric inhibition at baseline compared to healthy controls measued by task-related fMRI and by TMS iSP and SICI.\n\nThe degree of interhemispheric inhibition in stroke patients will normalize during recovery and be similar to normal controls at the last follow-up after 12 weeks.\n\nFurther, the degree of normalization of the interhemispheric inhibition in stroke patients will be proportional to degree of improvement of the upper-extremity measured by UE-FMA."},"conditionsModule":{"conditions":["Ischemic Stroke","Upper Extremity Hemiparesis"],"keywords":["non-invasive brain stimulation","transcranial direct current stimulation","effective connectivity","functional connectivity","Fugl-Meyer Assessment","Functional Magnetic Resonance Imaging"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"SUPPORTIVE_CARE","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":60,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Active Transcranial Direct Current Stimulation","type":"ACTIVE_COMPARATOR","description":"Anodal TDCS 1mV for 2x 20 minutes.","interventionNames":["Device: Active Transcranial Direct Current Stimulation"]},{"label":"Sham stimulation","type":"SHAM_COMPARATOR","description":"2x 20 minutes of sham stimulation (30 sec ramp up, followed by current of 0 for 18.5 minutes followed by 30 sec ramp down).","interventionNames":["Device: Sham stimulation"]}],"interventions":[{"type":"DEVICE","name":"Active Transcranial Direct Current Stimulation","description":"See arm/group description","armGroupLabels":["Active Transcranial Direct Current Stimulation"]},{"type":"DEVICE","name":"Sham stimulation","description":"See arm/group description","armGroupLabels":["Sham stimulation"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Upper-extremity motor outcome","description":"Difference in change in Upper-extremity Fugl-Meyer Assessment (UE-FMA) score. Range 0-66.","timeFrame":"From baseline to four months"}],"secondaryOutcomes":[{"measure":"Upper-extremity function","description":"Difference in change in Action Reach Arm Test (ARAT) score. Range 0-57. High scores mean a better outcome.","timeFrame":"From baseline to four months"},{"measure":"Stroke severity","description":"Difference in change in National Health Institutes Stroke Scale (NIHSS). Range 0-42. High scores mean a better outcome.","timeFrame":"From baseline to four months"},{"measure":"Stroke disability","description":"Difference in change in Modified Rankin Scale (mRS). Range 0-6. Lower scores mean a better outcome.","timeFrame":"From baseline to four months"},{"measure":"ADL performance","description":"Difference in change in Bartel's 20-item Index (BI-20). Range 0-100. Higher scores mean better outcome.","timeFrame":"From baseline to four months"},{"measure":"Gait speed","description":"Difference in change in 10 Meter Walk Test (10MWT) in minutes:sec.","timeFrame":"From baseline to four months"},{"measure":"Physical Activity","description":"Difference in change in Physical Activity Scale 2.0 (PAS2). The answers will be translated into a Metabolic Equivalent of Task (MET)-score. The higher MET-score the higher level of activity.","timeFrame":"From baseline to four months"},{"measure":"Montreal Cognitive Assessment","description":"Difference in change in Montreal Cognitive Assessment (MoCA) score. Score range 0-30. Higher scores mean a better outcome.","timeFrame":"From baseline to four months"},{"measure":"Symbol Digit Modalities Test","description":"Difference in change in Symbol Digit Modalities Test (SDMT) score. Score range 0-110. Higher scores mean a better outcome.","timeFrame":"From baseline to four months"},{"measure":"Health-related quality of life","description":"Difference in change in EQ-5D-5L score. Range 1 to 20, a high score means low health-related quality of life. Includes a 0-100 visual analogue scale for overall percieved quality of life.","timeFrame":"From baseline to four months"},{"measure":"Becks Depression Inventory (BDI)","description":"Difference in change in BDI-II score. Score range 0-63. Higher score means increased risk of depression.","timeFrame":"From baseline to four months"},{"measure":"Fatigue Severity Scale (FSS)","description":"Difference in change in FSS score. Score range 0-7. Higher score means increased fatigue severity.","timeFrame":"From baseline to four months"},{"measure":"WHO-5 Well-Beeing Index","description":"Difference in change in WHO-5 score. Score range 0-100. Higher score means better quality of life.","timeFrame":"From baseline to four months"},{"measure":"Biomarker of inflammation and exercise","description":"Difference in change in serum level Cathepsin-B (unit mikro gram/L)","timeFrame":"From baseline to four months"},{"measure":"MRI - Cerebral bloodflow","description":"Change in cerebral blood flow measured with arterial spin labeling (ASL) during rest","timeFrame":"From baseline to four months"},{"measure":"fMRI - Effective connectivity","description":"Change in activation patterns measured with blood-oxygen-level dependent (BOLD) during both single and bimanual task.","timeFrame":"From baseline to four months"},{"measure":"fMRI - Interhemispheric inhibition","description":"Change in activation pattern measured by blood-oxygen-level dependent (BOLD) during both single and bimanual task.","timeFrame":"From baseline to four months"},{"measure":"fMRI - Laterality Index","description":"Change in activation pattern for hemispheric dominance measured by the ratio of active fMRI voxels in each hemisphere.","timeFrame":"From baseline to four months"},{"measure":"MRI - Corticospinal integrity","description":"Change in corticospinal integrity measured by diffusion MRI.","timeFrame":"From baseline to four months"},{"measure":"MRI - Infarct lesion load","description":"Difference in change in size of infarct lesion meaured by structural MRI.","timeFrame":"From baseline to four months"}],"otherOutcomes":[{"measure":"Brain Derived Neutrotrophic Factor (BDNF) genetic polymorphism","description":"Determination of BDNF genetic variant - either Val66Met variant or wildtype.","timeFrame":"Baseline"},{"measure":"Feasibility of intervention","description":"Completion of intervention in the active vs. control group","timeFrame":"From baseline to four months"},{"measure":"TMS - motor evoked potential","description":"Determination of existence of a MEP-response by TMS as an indicator of cortico-spinal tract integrity. Prognostic marker of motor recovery.","timeFrame":"Baseline"},{"measure":"TMS - Ipsilateral silent period (iSP)","description":"Determination of degree of interhemispheric inhibition unaffected vs. affected hemisphere","timeFrame":"Baseline"},{"measure":"TMS - Short latency intracortical inhibition (SICI)","description":"Determination of degree of interhemispheric inhibition unaffected vs. affected hemisphere","timeFrame":"Baseline"},{"measure":"TMS - cortico-motor conduction time (CMCT)","description":"Determination of conduction time from stimulation of cortical neurons to response measured in a peripheral muscle (FDI)","timeFrame":"Baseline"}]},"eligibilityModule":{"eligibilityCriteria":"Patients - Inclusion Criteria:\n\n1. Age \\>18 years\n2. Ischemic stroke confirmed by clinical and imaging criteria\n3. Hemiparesis including reduced upper-extremity function\n4. Location of stroke either cortically involving middle cerebral artery or the anterior cerebral artery circulation or subcortical (involving thalamus, basal ganglia).\n5. NIHSS score \\>2 and \\<8\n6. Modified Rankin Scale (mRS) â‰¤ 3\n7. Index of stroke within 4 weeks of inclusion\n8. Signed informed consent\n\nPatients - Exclusion Criteria:\n\n1. \\>50% stenosis of extra- or intracranial artery as well as vascular malformations or aneurisms detected by brain CT-angiography.\n2. Exclusively ischemic stroke in spine, pons, brainstem, medulla or cerebellum.\n3. History of seizures, epilepsy, anxiety, dementia alcohol- or drug abuse.\n4. Prior serious head injury or neurosurgery\n5. Frequent severe headaches or migraine.\n6. Pregnancy or breastfeeding\n7. Current use of neuro-receptor/transmitter modulating medication, or medication interfering with seizure threshold (such as antiepileptic medication, some antidepressants, anxiety medication, antihistamines, stimulant drugs for attention deficit hyperactivity disorder).\n8. Pacemaker, implantable cardiac device unit (ICD-unit), metal fragments or other materials implanted not compatible with MRI (see appendix B).\n9. Claustrophobia\n10. Prior adverse effect to TDCS or Transcranial Magnetic Stimulation.\n11. Not able to provide informed consent.\n12. Terminally ill or short life expectancy.\n\nHealthy controls - Inclusion criteria:\n\n1. Age between \\>18 years (matched to patients)\n2. Sex and age matched to patients\n3. Able bodied\n4. Have the ability to comply with all requirements of the study protocol, as determined by the investigator\n5. No history of stroke or dementia\n6. Eligible for MRI and TMS\n\nHealthy controls - Exclusion Criteria:\n\n1. History of neurologic disease\n2. History of cerebral haemorrhage or brain damage\n3. Pregnancy\n4. Pacemaker or other implanted electronic devices\n5. Claustrophobia\n6. Psychiatric disorder\n7. Epilepsy or close relatives suffering from epilepsy\n8. Migraine\n9. Any contraindication to MRI or TMS","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Christina Krusse, MD, Prof","role":"CONTACT","phone":"+4538681233","email":"christina.kruuse@regionh.dk"},{"name":"Mia Kolmos, MD","role":"CONTACT","phone":"+4538681375","email":"mia.kolmos@regionh.dk"}],"overallOfficials":[{"name":"Christina Kruuse, MD, Prof","affiliation":"Herlev Gentofte Hospital, Department of Neurology","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Copenhagen University Department of Nutrition and Exercise","status":"RECRUITING","city":"Copenhagen","zip":"2200","country":"Denmark","contacts":[{"name":"Anke Karabanov, MSc, PhD","role":"CONTACT","phone":"+4535328039","email":"anke@nexs.ku.dk"},{"name":"Anke Karabanov, MSc, PhD","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":55.67594,"lon":12.56553}},{"facility":"Department of Neurology, Herlev Gentofte Hospital","status":"RECRUITING","city":"Herlev","zip":"2730","country":"Denmark","contacts":[{"name":"Christina Kruuse, MD, Prof","role":"CONTACT","phone":"+4538681233"},{"name":"Mia Kolmos, MD","role":"CONTACT","phone":"+4538681375","email":"mia.kolmos@regionh.dk"},{"name":"Christina Kruuse, MD, Prof","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Mia Kolmos, MD","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":55.72366,"lon":12.43998}},{"facility":"Danish Research Centre for Magnetic Resonance","status":"RECRUITING","city":"Hvidovre","zip":"2650","country":"Denmark","contacts":[{"name":"Hartwig R Siebner, MD, Prof","role":"CONTACT","phone":"+4538626541","email":"hartwig.roman.siebner@regionh.dk"},{"name":"Axel Thielscher, MSc, Prof","role":"CONTACT","phone":"+4538623326","email":"axelt@drcmr.dk"},{"name":"Hartwig R Siebner, MD, Prof","role":"SUB_INVESTIGATOR"},{"name":"Axel Thielscher, MSc, Prof","role":"SUB_INVESTIGATOR"},{"name":"Marie Louise Liu, MD","role":"SUB_INVESTIGATOR"}],"geoPoint":{"lat":55.65719,"lon":12.47364}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"IPD can be accessed upon reasonable request and after evaluation from the investigator."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000010291","term":"Paresis"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M20634","name":"Muscle Weakness","relevance":"LOW"},{"id":"M12894","name":"Paresis","asFound":"Hemiparesis","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"}]}},"hasResults":false}